{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:16:31Z","timestamp":1790709391585,"version":"4.1.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.semcancer.2020.03.002","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T12:46:58Z","timestamp":1583758018000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma"],"prefix":"10.1016","volume":"72","author":[{"given":"Andrea","family":"Ronchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Zito Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Accardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Immacolata","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2020.03.002_bib0005","first-page":"1052","article-title":"Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods","volume":"49","author":"Kinsel","year":"1989","journal-title":"Cancer Res."},{"issue":"February (1)","key":"10.1016\/j.semcancer.2020.03.002_bib0010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/bbrc.1997.7893","article-title":"The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro","volume":"243","author":"Ogawa","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0015","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1530\/JME-15-0254","article-title":"What\u2019s new in estrogen receptor action in the female reproductive tract","volume":"56","author":"Hewitt","year":"2016","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0020","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.coph.2010.09.007","article-title":"The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer","volume":"10","author":"McDonnell","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0025","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1530\/JME-12-0097","article-title":"The ligand\u2010mediated nuclear mobility and interaction with estrogen\u2010responsive elements of estrogen receptors are subtype specific","volume":"49","author":"Muyan","year":"2012","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0030","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbamcr.2009.06.001","article-title":"Regulation of mitochondrial respiratory chain biogenesis by estrogens\/estrogen receptors and physiological, pathological and pharmacological implications","volume":"1793","author":"Chen","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.semcancer.2020.03.002_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.mce.2015.04.017","article-title":"Estrogen receptor alpha\u201036 (ER\u2010\u03b136): a new player in human breast cancer","volume":"418","author":"Wang","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0040","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-med-042513-015127","article-title":"Targeting HER2 for the treatment of breast cancer","volume":"66","author":"Rimawi","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0050","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"July (20)","key":"10.1016\/j.semcancer.2020.03.002_bib0055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society Of Clinical Oncology\/College of american pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"November (31)","key":"10.1016\/j.semcancer.2020.03.002_bib0060","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1200\/JCO.2011.36.0107","article-title":"Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy","volume":"29","author":"Tse","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"June (12)","key":"10.1016\/j.semcancer.2020.03.002_bib0065","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.30592","article-title":"Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer","volume":"123","author":"Donaldson","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.002_bib0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5858\/arpa.2016-0201-OA","article-title":"RAI1 alternate probe identifies additional breast cancer cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory","volume":"141","author":"Hui","year":"2017","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"October (4)","key":"10.1016\/j.semcancer.2020.03.002_bib0075","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/his.13253","article-title":"HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category","volume":"71","author":"Holzschuh","year":"2017","journal-title":"Histopathology"},{"issue":"March (7)","key":"10.1016\/j.semcancer.2020.03.002_bib0080","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"issue":"April (4)","key":"10.1016\/j.semcancer.2020.03.002_bib0085","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/s12885-017-3670-1","article-title":"Clinicopathological and prognostic significance of programmed death ligand\u20101 expression in breast cancer: a meta\u2010analysis","volume":"17","author":"Kim","year":"2017","journal-title":"BMC Cancer"},{"issue":"January (1)","key":"10.1016\/j.semcancer.2020.03.002_bib0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.emboj.7600912","article-title":"Structural basis for Gas6-Axl signalling","volume":"25","author":"Sasaki","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0100","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1096\/fj.04-2532fje","article-title":"C1-TEN is a negative regulator of the Akt\/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration","volume":"19","author":"Hafizi","year":"2005","journal-title":"FASEB J."},{"issue":"June (25)","key":"10.1016\/j.semcancer.2020.03.002_bib0105","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1038\/onc.2011.13","article-title":"Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a\/b in solid cancer","volume":"30","author":"Mudduluru","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2020.03.002_bib0110","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/jnci\/83.3.154","article-title":"Breast cancer prognostic factors: evaluation guidelines","volume":"83","author":"McGuire","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0115","first-page":"3","article-title":"Breast cancer, version 4","volume":"16","author":"Gradishar","year":"2017"},{"issue":"August (9793)","key":"10.1016\/j.semcancer.2020.03.002_bib0120","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2020.03.002_bib0125","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1002\/1097-0142(19801215)46:12+<2838::AID-CNCR2820461421>3.0.CO;2-A","article-title":"Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy","volume":"46","author":"Manni","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2020.03.002_bib0130","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","journal-title":"Lancet"},{"issue":"October (10001)","key":"10.1016\/j.semcancer.2020.03.002_bib0135","first-page":"1341","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","journal-title":"Lancet"},{"issue":"September (17)","key":"10.1016\/j.semcancer.2020.03.002_bib0140","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jnci\/dji249","article-title":"Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance","volume":"97","author":"Arpino","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"September (9)","key":"10.1016\/j.semcancer.2020.03.002_bib0145","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/modpathol.2013.60","article-title":"Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss","volume":"26","author":"Braun","year":"2013","journal-title":"Mod. Pathol."},{"issue":"February (3)","key":"10.1016\/j.semcancer.2020.03.002_bib0150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.756","article-title":"Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study","volume":"110","author":"Purdie","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"November (11)","key":"10.1016\/j.semcancer.2020.03.002_bib0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/jcp.49.11.920","article-title":"Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status","volume":"49","author":"Collett","year":"1996","journal-title":"J. Clin. Pathol."},{"issue":"September (25)","key":"10.1016\/j.semcancer.2020.03.002_bib0160","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","article-title":"Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98","volume":"25","author":"Viale","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"September (3)","key":"10.1016\/j.semcancer.2020.03.002_bib0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10555-016-9631-3","article-title":"Estrogen, progesterone, and HER2\/neu receptor discordance between primary and metastatic breast tumours-a review","volume":"35","author":"Yeung","year":"2016","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.002_bib0170","doi-asserted-by":"crossref","first-page":"R6","DOI":"10.1186\/bcr1639","article-title":"Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients","volume":"9","author":"Dunnwald","year":"2007","journal-title":"Breast Cancer Res."},{"issue":"June (11)","key":"10.1016\/j.semcancer.2020.03.002_bib0175","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/cncr.21030","article-title":"Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma","volume":"103","author":"Grann","year":"2005","journal-title":"Cancer"},{"issue":"December (12)","key":"10.1016\/j.semcancer.2020.03.002_bib0180","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/modpathol.3800229","article-title":"Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study","volume":"17","author":"Mohsin","year":"2004","journal-title":"Mod. Pathol."},{"issue":"January (2)","key":"10.1016\/j.semcancer.2020.03.002_bib0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055901","article-title":"Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma","volume":"8","author":"Reyal","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.03.002_bib0195","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients","volume":"96","author":"de Azambuja","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2020.03.002_bib0200","first-page":"30","article-title":"Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: a retrospective cohort study","volume":"24","author":"Kamranzadeh","year":"2019","journal-title":"Res. Med. Sci."},{"issue":"June (6)","key":"10.1016\/j.semcancer.2020.03.002_bib0205","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/modpathol.2015.38","article-title":"An international study to increase concordance in Ki67 scoring","volume":"28","author":"Polley","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0210","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0215","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-015-3559-0","article-title":"Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients","volume":"153","author":"Petrelli","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.002_bib0220","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju093","article-title":"Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer","volume":"106","author":"Anderson","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl. 2","key":"10.1016\/j.semcancer.2020.03.002_bib0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000055404","article-title":"HER2 as a prognostic factor in breast cancer","volume":"61","author":"M\u00e9nard","year":"2001","journal-title":"Oncology"},{"issue":"August (5)","key":"10.1016\/j.semcancer.2020.03.002_bib0230","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41523-019-0122-x","article-title":"Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO\/CAP ISH group 4 breast cancer","volume":"29","author":"Gupta","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"August (3)","key":"10.1016\/j.semcancer.2020.03.002_bib0235","article-title":"Assessing the impact of the 2018 American Society of Clinical Oncology\/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma","author":"Murray","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0240","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0245","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"issue":"April (7)","key":"10.1016\/j.semcancer.2020.03.002_bib0250","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.002_bib0255","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1186\/bcr2334","article-title":"Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes","volume":"11","author":"Stefansson","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0260","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1038\/s41467-018-06052-0","article-title":"Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq","volume":"9","author":"Karaayvaz","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.002_bib0265","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1097\/MD.0000000000000515","article-title":"Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"issue":"February (2)","key":"10.1016\/j.semcancer.2020.03.002_bib0270","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immunecheckpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"February (3)","key":"10.1016\/j.semcancer.2020.03.002_bib0275","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"March (3)","key":"10.1016\/j.semcancer.2020.03.002_bib0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."},{"issue":"January (1)","key":"10.1016\/j.semcancer.2020.03.002_bib0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol."},{"issue":"21","key":"10.1016\/j.semcancer.2020.03.002_bib0290","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"November (27)","key":"10.1016\/j.semcancer.2020.03.002_bib0295","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","author":"Schmid","year":"2019","journal-title":"Lancet Oncol."},{"issue":"March (3)","key":"10.1016\/j.semcancer.2020.03.002_bib0300","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/PAS.0000000000000780","article-title":"PD-L1 expression and intratumoral heterogeneity across breast Cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors","volume":"41","author":"Dill","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"issue":"October (1)","key":"10.1016\/j.semcancer.2020.03.002_bib0305","doi-asserted-by":"crossref","first-page":"14356","DOI":"10.1038\/s41598-019-50898-3","article-title":"Expression of PD-1\/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters","volume":"9","author":"Yuan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204513","article-title":"Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype","volume":"13","author":"Harano","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2020.03.002_bib0315","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/0008-5472.CAN-16-3427","article-title":"Identification of interacting stromal axes in triple-negative breast cancer","volume":"77","author":"Saleh","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0320","doi-asserted-by":"crossref","first-page":"IA23","DOI":"10.1158\/1538-7445.TME16-IA23","article-title":"Abstract IA23: deconvolution of the triple-negative breast cancer microenvironment","volume":"76","author":"Saleh","year":"2016","journal-title":"Cancer Res."},{"issue":"March (3)","key":"10.1016\/j.semcancer.2020.03.002_bib0325","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAS.0000000000001400","article-title":"Heterogeneity of PD-L1 expression in lung mixed adenocarcinomas and adenosquamous carcinomas","volume":"44","author":"Zito Marino","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"issue":"May (5)","key":"10.1016\/j.semcancer.2020.03.002_bib0330","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14737140.2017.1301207","article-title":"Predictive biomarkers along gastric cancer pathogenetic pathways","volume":"17","author":"Panarese","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0335","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0340","first-page":"5853","article-title":"Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome","volume":"53","author":"Peltomaki","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0345","first-page":"159","article-title":"Microsatellite instability in colorectal cancer","volume":"17","author":"Nojadeh","year":"2018","journal-title":"EXCLI J."},{"issue":"April (4)","key":"10.1016\/j.semcancer.2020.03.002_bib0350","first-page":"839","article-title":"Microsatellite instability is uncommon in breast cancer","volume":"5","author":"Anbazhagan","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.03.002_bib0355","series-title":"Proceedings of the 2018 San Antonio Breast Cancer Symposium","article-title":"Microsatellite instability in triple negative breast cancers [abstract]","author":"Kurata","year":"2019"},{"issue":"December (4)","key":"10.1016\/j.semcancer.2020.03.002_bib0360","doi-asserted-by":"crossref","first-page":"pky056","DOI":"10.1093\/jncics\/pky056","article-title":"Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability","volume":"2","author":"Fusco","year":"2018","journal-title":"JNCI Cancer Spectr."},{"issue":"October (10)","key":"10.1016\/j.semcancer.2020.03.002_bib0365","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/annonc\/mdp062","article-title":"Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer","volume":"20","author":"Linderholm","year":"2009","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.002_bib0370","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2353\/ajpath.2008.070181","article-title":"Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels","volume":"172","author":"Herv\u00e9","year":"2008","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.002_bib0375","first-page":"2256","article-title":"The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer","volume":"61","author":"Linderholm","year":"2001","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.semcancer.2020.03.002_bib0380","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1002\/cncr.30170","article-title":"Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: results from the GINECO A-TaXel phase 2 study","volume":"122","author":"Ferrero","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.002_bib0385","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/annonc\/mdw665","article-title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","volume":"28","author":"Bell","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.002_bib0390","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.clbc.2018.12.008","article-title":"Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer-A phase II trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib","volume":"19","author":"Symonds","year":"2019","journal-title":"Clin. Breast Cancer"},{"issue":"5\u20136","key":"10.1016\/j.semcancer.2020.03.002_bib0395","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12672-015-0232-3","article-title":"Androgen receptor biology in triple negative breast cancer: a case for classification as AR+ or quadruple negative disease","volume":"6","author":"Barton","year":"2015","journal-title":"Horm. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.002_bib0400","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.002_bib0405","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdw067","article-title":"A phase II trial of abiraterone acetate plus prednisone in patients with triplenegative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)","volume":"27","author":"Bonnefoi","year":"2016","journal-title":"Ann. Oncol."},{"issue":"April (8)","key":"10.1016\/j.semcancer.2020.03.002_bib0410","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7","article-title":"Expression of c-met is a strong independent prognostic factor in breast carcinoma","volume":"82","author":"Ghoussoub","year":"1998","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.002_bib0415","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/1078-0432.CCR-11-2830","article-title":"cMET and phospho-cMET protein levels in breast cancers and survival outcomes","volume":"18","author":"Raghav","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.002_bib0420","first-page":"225","article-title":"Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma","volume":"148","author":"Tuck","year":"1996","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.002_bib0425","first-page":"1630","article-title":"Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer","volume":"54","author":"Yamashita","year":"1994","journal-title":"Cancer Res."},{"issue":"June (1)","key":"10.1016\/j.semcancer.2020.03.002_bib0430","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/bjc.2015.187","article-title":"Differential p16\/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients","volume":"113","author":"Jennings","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"October (1)","key":"10.1016\/j.semcancer.2020.03.002_bib0435","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cancergencyto.2006.04.011","article-title":"Cytogenetic and molecular genetic changes in malignant mesothelioma","volume":"170","author":"Musti","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.002_bib0440","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.2016-0229","article-title":"Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients","volume":"22","author":"Tolaney","year":"2016","journal-title":"Oncologist"},{"issue":"March (6)","key":"10.1016\/j.semcancer.2020.03.002_bib0445","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1158\/0008-5472.CAN-07-2661","article-title":"AXL is a potential target for therapeutic intervention in breast cancer progression","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res."},{"issue":"February (2)","key":"10.1016\/j.semcancer.2020.03.002_bib0450","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3892\/ol.2016.5524","article-title":"Expression of Axl and its prognostic significance in human breast cancer","volume":"13","author":"Jin","year":"2017","journal-title":"Oncol. Lett."},{"issue":"May (8)","key":"10.1016\/j.semcancer.2020.03.002_bib0455","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.7150\/thno.15083","article-title":"Gas6\/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt\/GSK-3\u03b2\/\u03b2-catenin signaling","volume":"6","author":"Wang","year":"2016","journal-title":"Theranostics"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20300602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X20300602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:47:17Z","timestamp":1760917637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X20300602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":91,"alternative-id":["S1044579X20300602"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.002","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}